Sugi Predict

Sugi Predict / Compounds / SCHEMBL4294055

SCHEMBL4294055

SCHEMBL4294055

COc1ccc2c(c1)C(=O)C(O)=CC2=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.53
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA4 P22748 1/20 0.49
▸ CA7 P43166 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ LCK P06239 3/20 0.48
▸ PRKACA P17612 1/20 0.47
▸ PRKACG P22612 1/20 0.47
▸ PRKACB P22694 1/20 0.47
▸ ESR1 P03372 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ GAPDH P04406 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ APP P05067 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SNCA P37840 1/20 0.43
▸ USP8 P40818 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406983 1.00 PTPN1 (0.53) PTPN1CA1CA2CA4CA7
SCHEMBL30003052 0.93 PTPN1 (0.49) PTPN1CA1CA2CA4CA7
SCHEMBL9178172 0.93 PTPN1 (0.49) PTPN1CA1CA2CA4CA7
SCHEMBL5809726 0.81 IDO1 (0.62) PTPN1CA1CA2CA4CA7
SCHEMBL12760698 0.81 PTPN1 (0.54) PTPN1CA1CA2CA4CA7
SCHEMBL10579406 0.79 PTPN1 (0.53) PTPN1CA1CA2CA4CA7
SCHEMBL5810326 0.78 LCK (0.56) PTPN1CA1CA2CA4CA7
SCHEMBL23111388 0.77 CA1 (0.57) PTPN1CA1CA2CA4CA7
SCHEMBL7451901 0.77 CA1 (0.57) PTPN1CA1CA2CA4CA7
SCHEMBL2252533 0.77 CA1 (0.57) PTPN1CA1CA2CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4888026-A HAIR DYES; OXIDATION RESISTANCE L'OREAL (FR) 1989-12-19 — — US claimed
CN-117942329-A Application of compound in preparation of medicine for treating and/or preventing cerebral apoplexy 中国药科大学 2024-04-30 — — CN disclosed
WO-2023142518-A1 HYDROXYNAPHTHALENONE-PHENYLBORONIC ACID COMPOUND, PREPARATION METHOD, AND USE 中国药科大学 2023-08-03 — — WO disclosed
CN-114195814-B Hydroxy naphthalenone-phenylboronic acid compound, preparation method and application 中国药科大学 2023-07-21 — — CN disclosed
CN-114195814-A Hydroxy naphthalenone-phenylboronic acid compound, preparation method and application 中国药科大学 2022-03-18 — — CN disclosed
CN-110156822-B Naphthol-phenylboronic acid compound and preparation method and application thereof 中国药科大学 2021-07-09 — — CN disclosed
EP-2877455-B1 FUSED QUINONIC COMPOUNDS CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A (ES) 2016-08-17 — — EP disclosed
EP-2877455-B1 FUSED QUINONIC COMPOUNDS CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A (ES) 2016-08-17 — — EP disclosed
US-20150175585-A1 FUSED QUINONIC COMPOUNDS CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.) (ES) 2015-06-25 — — US disclosed
US-20150175585-A1 FUSED QUINONIC COMPOUNDS CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.) (ES) 2015-06-25 — — US disclosed
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases SLIL BIOMEDICAL CORPORATION (US) 2004-01-08 — — US disclosed
US-6649587-B1 Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B SLIL BIOMEDICAL CORPORATION 2003-11-18 — — US disclosed
US-20030013677-A1 QUINONES AS DISEASE THERAPIES CELLGATE, INC. 2003-01-16 — — US disclosed
US-20020183512-A1 Novel quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-12-05 — — US disclosed
US-6482943-B1 Quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-11-19 — — US disclosed
EP-1185493-A1 QUINONES FOR TREATMENT OF DISEASES SLIL Biomedical Corporation (US) 2002-03-13 — — EP disclosed
EP-1173223-A2 CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES Slil Biomedical Corporation (US) 2002-01-23 — — EP disclosed
WO-2000066175-A2 CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES SLIL BIOMEDICAL CORPORATION (US) 2000-11-09 — — WO disclosed
WO-2000066528-A2 QUINONES FOR TREATMENT OF DISEASES SLIL BIOMEDICAL CORPORATION (US) 2000-11-09 — — WO disclosed
US-4888026-A HAIR DYES; OXIDATION RESISTANCE L'OREAL (FR) 1989-12-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175585-A1 FUSED QUINONIC COMPOUNDS STAT3, STAT1, JAK2 PTPN1 318/4885CA1 4803/4885CA2 4505/4885
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CTSB, CTSL, CTSV PTPN1 4034/4885CA1 1486/4885CA2 3220/4885
US-20030013677-A1 QUINONES AS DISEASE THERAPIES NQO1, NDUFV2, SDHB PTPN1 3153/4885CA1 4664/4885CA2 4489/4885
US-20020183512-A1 Novel quinones as disease therapies NQO1, NDUFV2, SDHB PTPN1 3247/4885CA1 4628/4885CA2 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.